RalphG.ZinnerMD

PubMed

• 37 citations
  Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
  Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, Siqing Fu, Gerald S. Falchook
  Oncotarget. 2016-08-31
• 11 citations
  Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care
  Jyoti D. Patel, Luis Paz-Ares, Ralph Zinner, Fabrice Barlesi, Andrew Koustenis
  Clinical Lung Cancer. 2018-11-01
• 4 citations
  Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky.
  Christine Fillmore Brainson, Bin Huang, Quan Chen, Laurie E. McLouth, Chunyan He
  Clinical Lung Cancer. 2021-03-26

Journal Articles

• STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid f...  
  Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, Ma..., J Hematol Oncol, 1/1/2015
• A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)  
  Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, Redman MW, Gandara DR, Cancer, 1/1/2014
• Mutation profiling in Cholangiocarcinoma: Prognostic and Therapeutic implications  
  Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M, PLoS One, 1/1/2014
• Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit  
  Fu S, McQuinn LM, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul S, Tu D, Howard AN, Tsimberidou AM, Zinner RG, Hong DS, Kurzrock R, The Oncologist, 1/1/2013
• Combining erlotinib and cetuximab is associated with activity in patients with non small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or re...  
  Wheler J, Tsimberidou A, Falchook GS, Zinner R, Hong D, Fok Jansina, Fu S, Piha-Paul S, Naing A, Kurzrock R, Molecular Cancer Therapeutics, 1/1/2013
• Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer  
  Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Janku F, Zinner R, Laday S, Kies M, Tsimberidou AM, Invest New Drugs, 1/1/2013
• Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426  
  Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM, Schild SE, Zinner RG, J Clin Oncol, 1/1/2010
• Trastuzumab enters non-small cell lung cancer clinical trials  
  Zinner RG, Kim J, Herbst RS, Her2 in Oncol, 1/1/2000
• Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)  
  Zinner RG, Grul CV, Spigel DR, Obasauju C, International Journal of Oncology, 1/29/2015
• Join now to see all

Books/Book Chapters

• Handbook of Advanced Cancer Care 
  Chapter: Mesothelioma 
  Zinner REditors: Fisch MJ, Bruera.Cambridge University Press, Cambridge, United Kingdom2003
• Lung Cancer. 2, The M. D. Anderson Cancer Care Series 
  Chapter: Treatment of patients with advanced non-small cell lung cancer 
  Zinner REditors: Fossella FV, Komaki R, Putnam JB Jr., Buzdar AU, Freedman RS.Springer-Verlag, Inc, New York, NY2002

Abstracts/Posters

• Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study
  Kato S, Naing A, Falchook G, Holley VR, Velez-Bravo VM, Patel S, <b>Zinner RG</b>, Piha-Paul SA, Tsimberidou AM, Hong DS, Kurzrock R, Meric-Bernstam F, Janku, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR), 1/1/2015
• Phase I study of BPM 31510 (ubidecarenone) in patients with advanced solid tumors
  Shah MA, Yu p, Narain N, Sarangarajan R, Kiebish M, Vishnudas V, Sun Y, Rodrigues L, Akmaev VR, Brouwer S, Stevens J, Benaim E, Zinner R, Proc Am Assoc of Ca Res (AACR), 1/1/2015
• Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform
  Janku F, Huang1 HJ, Claes B, Falchook GS, Fu S, Tsimberidou AM, Hong DS, Naing A, Wheler JJ, Piha-Paul SA, Karp DD, Subbiah V, Zinner RG, Ramzanali N, Luthra R, Patel ..., Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR), 1/1/2015
• Phase 1 study of BPM 31510 (Ubidecarenone) in patients with advanced solid tumors (ST): Use of multiomics platform to evaluate reversal of Warburg effect
  Zinner R, Yu PP, Narain NR, Sarangarajan R, Kiebish M, Vishnudas V, Sun Y, Rodrigues L, Akmaev VR, Brouwer S, Stevens J, Benaim E, Shah MA, Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer
  Kato S, Janku F, Piha-Paul SA, Naing A, Karp DD, Tsimberidou AM, Subbiah V, Zinner R, Hwu W, Javle MM, Parkhurst KL, Ramzanali NM, Kurzrock R, Meric-Bernstam, Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Pazopanib (P) and trametinib (T) in advanced cholangiocarcinoma (CC): A phase Ib study
  Shroff R, O'Connor A, Gallagher D, Zahurak M, Rosner GL, Ohaji C, Sarorius-Mergenthaler S, Zinner R, Azad NS, Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer
  Kato s, Jardim DLF, Johnson FM, Subbiah V, Piha-Paul SA, Tsimberidou AM, Falchook GS, Karp DD, Wheler JJ, Zinner R, Janku F, Fu S, Dandu L, Browne E, Meric-Bernstam F,..., Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies
  Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Subbiah V, Tsimberidou AM, Kaseb AO, Oki Y, Zinner R, Patel S, Broavo VMV, Fana..., Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers
  Hong DS, Morris VK, El Osta BE, Fu S, Overman MJ, Piha-Paul SA, Subbiah V, Kee BK, Tsimberidou AM, Zinner R, Fogelman DR, Bellido J, Shrueiqi I, Meric-Bernstam F, Kope..., Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a...
  Piha-Paul SA, Goldstein JB, Hess KR, Fu S, Hong DS, Janku F, Karp DD, Naing A, Subbiah V, Tsimberidou AM, Wheler JJ, Zinner R, Mills GB, Meric-Bernstam F, Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment
  Kopetz S, Litzenburger B, Kinyua W, Sajan B, Subbiah V, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heyma..., Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy
  Wheler JJ, Yelensky R, Stephen B, Hong DS, Zinner R, Subbiah V, Fu S, Karp DD, Falchook GS, Naing A, Tsimberidou AM, Piha-Paul SA, Janku F, Li Y, Lee JJ, Miller MA, Me..., Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a phase 1 clinic
  George G, Iwuanyanwu EC, Anderson KO, Piha-Paul SA, Wheler JJ, Zinner R, Naing A, Tsimberidou AM, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS, Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center
  Wagne M, Hess KR, Hong DS, Tang C, Naing A, Fu S, Janku F, Piha-Paul SA, Zinner R, Wheler JJ, Tsimberidou AM, Patel S, Somaiah N, Ravi V, Benjamin RS, Meric-Bernstam F, Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implica...
  Subbiah V, Janku F, Tsimberidou AM, Naing A, Suubiah V, Wheler JJ, Zinner R, Eng C, Overman MJ, Kopetz S, Hong DS, Proc Am Assoc of Ca Res (AACR), 1/1/2015
• Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center
  Goldstein JB, Tang C, Hong DS, Subbiah V, Janku F, Hess KR, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler JJ, Zinner R, Javle MM, Varadhachary GR, Wolff RA, Fogelman ..., Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary...
  Subbiah IM, Varadhachary G, Tsimberidou AM, Wheler JJ, Subbiah V, Janku F, Chowdhuri SR, Zinner R, Hong DS, Proc Am Assoc of Ca Res (AACR), 1/1/2015
• Multiplex KRAS G12/G13 mutation testing of 16ng of unamplified cell-free DNA from plasma of patients with advanced cancers using Droplet Digital PCR
  Huang HJ, Shelton DN, Fu S, Piha-Paul SA, Tsimberidou AM, Zinner RG, Wheler JJ, Naing A, Hong DS, Falckook GS, Kopetz S, Luthra R, Kee BK, Karlin-Neumann GA, Meric-Ber..., Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR), 1/1/2015
• Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel...
  Subbia IM, Janku J, Tsimberidou AM, Nain A, Subbiah V, Wheler JJ, Zinner R, Eng C, Overman MJ, Kopetz S, Palmer GA, Hong DS, Proc Am Soc of Clin Onc (ASCO), 1/1/2015
• Safety Data Analyses for First-Line Pemetrexed Plus Carboplatin (Pem+Cb) in Nonsquamous Non-Small Cell Lung Cancer
  Okamoto I, Schuette W,Stinchcombe T, Rodrigues-Pereira J, Liu J, San Antonio B, John W, Chen J, Zinner RG, European Society of Medical Oncology (ESMO), 1/1/2014
• Safety Data Analyses for First-Line Pemetrexed Plus Carboplatin (Pem+Cb) in Nonsquamous Non-Small Cell Lung Cancer (ns-NSCLC), Safety Data Analyses for First-Line Peme...
  Okamoto I, Schuette W,Stinchcombe T, Rodrigues-Pereira J, Liu J, San Antonio B, John W, Chen J, Zinner RG, Chicago Mutlidiscipolinary Symposium in Thoracic Oncology, 1/1/2014
• An Indirect Comparison Of The Efficacy And Safety Of Pemetrexed-Carboplatin-Bevacizumab Followed By Pemetrexed-Bevacizumab Versus Pemetrexed-Carboplatin Followed By Pe...
  Patel J, Enatsu S, Li S, Socinski M, Ross H, Spigel D, Beck JT, Liu J, Ortuzar W, Guba S, Bonomi P, Govindan R, Zinner RG, IASLC Asia Pacific Lung Cancer Conference, 1/1/2014
• BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla)
  Huang HJ, Claes B. Falchook GS, Naing A, Piha-Paul SA, Tsimberidou AM, Zinner R, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Luthra R, K BK, Overman MJ, Kim K, Maert..., Proc Am Assoc of Ca Res (AACR), 1/1/2014
• A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies
  Bupathi M, Falchook GS, Hon DS, Subbiah IM, Piha-Paul SA, Karp DD, Saigal B, Zinner R, Wheler JJ, Tsimberidou AM, FuS, Sherman SI, Meric-Bernstam F, Subbiah V, Proc Am Soc of Clin Onc (ASCO), 1/1/2014
• A phase I trial of pazopanib and vorinostat: The role of TP53 mutations
  Hou M. Bellido J, Naing A, Falchook GS, Hess KR, Zinner R, Wheler, JJ, Subbiah V, Hong DS, Piha-Paul SA, Tsimberidou AM, Karp DD, Kurzrock R, Meric-Bernstam F, Fu S, Proc Am Soc of Clin Onc (ASCO), 1/1/2014
• Join now to see all

Lectures

• PRONOUNCE Study Results 
  2013 Annual Meeting, Chicago, Illinois, USA
• PRONOUNCE Study Results 
  American Society of Clinical Oncology, 2013 Annual Meeting, Chicago, Illinois, USA
• Making Cancer History 
  Osaka, Japan - 1/1/2005

Other

• Directed discovery of novel drug cocktails 
  Miller J, Zinner RG, Barrett B, Santa Fe Institute Working Paper
  1/1/2005